论文部分内容阅读
目的:观察卡铂与健择联合化疗方案治疗晚期非小细胞肺癌(NSCLC)患者的临床疗效及不良反应。方法:对27例晚期NSCLC患者采用卡铂加健择联合化疗方案进行化疗,按WHO疗效及毒副反应评价标准,完成2个周期以上治疗的患者进行临床疗效及不良反应评估。结果:有效率40.7%(11/27),中位缓解期为6.5个月,中位生存期8.6个月,1a生存率37%(10/27)。主要毒副反应为骨髓抑制和消化道反应,均能耐受。结论:CBP与GEM联合化疗方案治疗晚期NSCLC患者的临床疗效较好,不良反应较轻,患者的耐受性好。
Objective: To observe the clinical efficacy and side effects of carboplatin and gemcitabine in combination with chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). Methods: Twenty-seven patients with advanced NSCLC were treated with carboplatin and selective chemotherapy combined with chemotherapy. According to the WHO efficacy and toxicity evaluation criteria, the clinical efficacy and adverse reactions of two cycles were evaluated. Results: The effective rate was 40.7% (11/27), the median remission was 6.5 months, the median survival time was 8.6 months, and the 1a survival rate was 37% (10/27). The main side effects of bone marrow suppression and digestive tract reactions, can tolerate. Conclusion: The combination of CBP and GEM chemotherapy in the treatment of advanced NSCLC patients with good clinical efficacy, mild adverse reactions, patients with good tolerance.